Infectious DiseasesMass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial
MedXY Editorial Team
Highlight
- Mass administration of azithromycin to infants aged 1 to 11 months in Mali did not reduce mortality compared to placebo.
- The trial randomized 1151 villages to placebo, twice-yearly, or quarterly azithromycin administration, enrolling over 149,000 infants.
- Mortality rates were similar across the three groups with no statistically significant differences.
- Adverse event rates were low and comparable among groups, supporting safety but not efficacy in mortality reduction.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
